Microarray analysis of survival pathways in human PC-3 prostate cancer cells.

BACKGROUND Insulin-like growth factor 1 (IGF-1), transforming growth factor beta 1 (TGFbeta1), and interleukin 6 (IL-6), act as survival factors inhibiting chemotherapy-induced apoptosis in PC-3 human prostate cancer cells, in vitro. MATERIALS AND METHODS To study the intracellular pathways activated by these survival factors we performed a comparative genomic analysis using oligonucleotide microarray chips. A validation by real time-PCR was also performed for the genes of interest. RESULTS The expression data derived were analysed using various normalization algorithms. The differentially expressed genes were clustered and their ontological annotations were statistically tested to provide evidence for possible deregulated biological processes on the action of the aforementioned survival factors. Emphasis was given on the regulation and the role of the genes AKR1C1, SDPR and GADD45B in the survival pathways of prostate cancer cells, whose expression was also validated by real time-PCR. CONCLUSION The overall analyses reveal an overrepresentation of differentially expressed genes related to cellular processes such as cell cycle regulation, lipid metabolism and steroid biosynthesis.

[1]  Hongjuan Zhao,et al.  Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues , 2007, Journal of cellular physiology.

[2]  D. Peehl,et al.  Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. , 2006, Endocrinology.

[3]  C. Mitsiades,et al.  Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. , 2006, Anticancer research.

[4]  D. Tindall,et al.  Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence , 2006, Genes, chromosomes & cancer.

[5]  M. Koutsilieris,et al.  Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach , 2006, Expert opinion on investigational drugs.

[6]  M. Koutsilieris,et al.  Prostate cancer cell survival pathways activated by bone metastasis microenvironment. , 2005, Journal of musculoskeletal & neuronal interactions.

[7]  L. Chung,et al.  Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. , 2005, The Journal of urology.

[8]  Trevor M Penning,et al.  The roles of aldo-keto reductases in steroid hormone action. , 2004, Drug news & perspectives.

[9]  P. Hertzog,et al.  Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells. , 2004, The international journal of biochemistry & cell biology.

[10]  A. Ullrich,et al.  Mammary Gland Remodeling Depends on gp130 Signaling through Stat3 and MAPK* , 2004, Journal of Biological Chemistry.

[11]  M. Koutsilieris,et al.  Bone microenvironment‐related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC‐3 prostate cancer cells , 2004, The Prostate.

[12]  Zhou Wang,et al.  Gadd45γ is androgen-responsive and growth-inhibitory in prostate cancer cells , 2004, Molecular and Cellular Endocrinology.

[13]  M. Dimopoulos,et al.  Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. , 2004, Urology.

[14]  Zhou Wang,et al.  Gadd45gamma is androgen-responsive and growth-inhibitory in prostate cancer cells. , 2004, Molecular and cellular endocrinology.

[15]  C. Mitsiades,et al.  Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer , 2004, Clinical & Experimental Metastasis.

[16]  K. Pienta,et al.  Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.

[17]  Z. Culig.  Role of the androgen receptor axis in prostate cancer. , 2003, Urology.

[18]  Kyucheol Cho,et al.  Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways , 2003, Oncogene.

[19]  Y. Yen,et al.  Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. , 2003, The American journal of pathology.

[20]  C. Mitsiades,et al.  Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. , 2003, Endocrine-related cancer.

[21]  M. Koutsilieris,et al.  Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement , 2002, Molecular medicine.

[22]  J. Cheville,et al.  Metastatic prostate carcinoma to bone , 2002, Cancer.

[23]  J T Arnold,et al.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. , 2002, Endocrine-related cancer.

[24]  C. Mitsiades,et al.  A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  C. Mitsiades,et al.  Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer , 2001, Expert opinion on investigational drugs.

[26]  L. Deftos.  Prostate carcinoma , 2000, Cancer.

[27]  C. Mitsiades,et al.  Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer , 2000, Molecular medicine.

[28]  T. Chung,et al.  STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP , 2000, The Prostate.

[29]  K. Miyazono,et al.  Intracellular Signaling of the TGF‐β Superfamily by Smad Proteins , 1999 .

[30]  B. Foster,et al.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.

[31]  S. Gustincich,et al.  The human serum deprivation response gene (SDPR) maps to 2q32-q33 and codes for a phosphatidylserine-binding protein. , 1999, Genomics.

[32]  M. Koutsilieris,et al.  Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone‐refractory prostate cancer: Case report , 1999, The Prostate.

[33]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[34]  K. Miyazono,et al.  Intracellular signaling of the TGF-beta superfamily by Smad proteins. , 1999, Annals of the New York Academy of Sciences.

[35]  T. Tsujimura,et al.  Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. , 1998, Oncology reports.

[36]  M. Koutsilieris,et al.  Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. , 1998, Urology.

[37]  M. Sporn,et al.  The role of transforming growth factor‐β1, ‐β2, and ‐β3 in androgen‐responsive growth of NRP‐152 rat prostatic epithelial cells , 1998 .

[38]  M. Sporn,et al.  The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. , 1998, Journal of cellular physiology.

[39]  T. Visakorpi,et al.  Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.

[40]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[41]  S. Gustincich,et al.  Serum deprivation response gene is induced by serum starvation but not by contact inhibition. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[42]  M. Susin,et al.  Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. , 1993, Cancer investigation.

[43]  G. Roodman,et al.  Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. , 1992, Endocrinology.

[44]  G. Roodman.  Perspectives: Interleukin‐6: An osteotropic factor? , 1992 .

[45]  G. Roodman.  Interleukin-6: an osteotropic factor? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.